Synopsys Responds to the European Commission Approving its Proposed Acquisition of Ansys in Phase 1
Synopsys announced that the European Commission (EC) has approved its proposed acquisition of Ansys in Phase 1, marking significant progress in obtaining regulatory clearances. The company highlighted recent developments including the UK CMA's provisional acceptance of remedies for Phase 1 approval and the expiration of the U.S. HSR Act waiting period.
The company is actively working with the FTC on proposed remedies review, while China SAMR has officially accepted their filing. The merger aims to address growing customer demands for integrated EDA and Simulation and Analysis (S&A) software solutions. Synopsys maintains its expectation to close the transaction in the first half of 2025, citing strong customer support for the merger.
Synopsys ha annunciato che la Commissione Europea (CE) ha approvato la sua proposta di acquisizione di Ansys nella Fase 1, segnando un progresso significativo nell'ottenimento delle autorizzazioni regolatorie. L'azienda ha evidenziato sviluppi recenti, inclusa l'accettazione provvisoria da parte della CMA del Regno Unito delle soluzioni per l'approvazione della Fase 1 e la scadenza del periodo di attesa previsto dall'HRS Act degli Stati Uniti.
L'azienda sta attivamente collaborando con la FTC per la revisione delle soluzioni proposte, mentre la SAMR cinese ha ufficialmente accettato la loro richiesta. La fusione mira a rispondere alle crescenti richieste dei clienti per soluzioni software integrate di EDA e Simulazione e Analisi (S&A). Synopsys mantiene la propria aspettativa di chiudere la transazione nel primo semestre del 2025, citando un forte supporto dei clienti per la fusione.
Synopsys anunció que la Comisión Europea (CE) ha aprobado su propuesta de adquisición de Ansys en la Fase 1, marcando un progreso significativo en la obtención de autorizaciones regulatorias. La empresa destacó desarrollos recientes, incluida la aceptación provisional por parte de la CMA del Reino Unido de las soluciones para la aprobación de la Fase 1 y la expiración del período de espera de la Ley HSR de EE. UU.
La empresa está trabajando activamente con la FTC en la revisión de las soluciones propuestas, mientras que la SAMR de China ha aceptado oficialmente su presentación. La fusión tiene como objetivo abordar la creciente demanda de los clientes por soluciones de software integradas de EDA y Simulación y Análisis (S&A). Synopsys mantiene su expectativa de cerrar la transacción en la primera mitad de 2025, citando un fuerte apoyo de los clientes para la fusión.
Synopsys는 유럽연합(EU) 집행위원회가 Ansys 인수 제안을 1단계에서 승인했다고 발표하며, 이는 규제 승인을 받기 위한 중요한 진전을 의미합니다. 이 회사는 영국 CMA가 1단계 승인을 위한 구제책을 잠정적으로 수용한 최근 발전과 미국 HSR 법의 대기 기간이 만료된 사실을 강조했습니다.
이 회사는 FTC와 제안된 구제책 검토를 위해 활발히 협력하고 있으며, 중국 SAMR은 공식적으로 그들의 신청서를 수용했습니다. 이 합병은 통합 EDA 및 시뮬레이션 및 분석(S&A) 소프트웨어 솔루션에 대한 고객의 증가하는 요구를 해결하는 것을 목표로 하고 있습니다. Synopsys는 합병에 대한 고객의 강력한 지원을 인용하며 2025년 상반기 내에 거래를 마무리할 것으로 기대하고 있습니다.
Synopsys a annoncé que la Commission Européenne (CE) a approuvé sa proposition d'acquisition de Ansys en Phase 1, marquant un progrès significatif dans l'obtention des autorisations réglementaires. L'entreprise a mis en avant les développements récents, y compris l'acceptation provisoire des remedies par la CMA du Royaume-Uni pour l'approbation de la Phase 1 et l'expiration de la période d'attente de la loi HSR aux États-Unis.
L'entreprise travaille activement avec la FTC sur l'examen des remedies proposées, tandis que la SAMR de Chine a officiellement accepté leur dossier. La fusion vise à répondre à la demande croissante des clients pour des solutions logicielles intégrées d'EDA et de simulation et d'analyse (S&A). Synopsys maintient son attente de clôturer la transaction au cours du premier semestre 2025, citant un fort soutien des clients pour la fusion.
Synopsys hat bekannt gegeben, dass die Europäische Kommission (EK) den Vorschlag zur Übernahme von Ansys in Phase 1 genehmigt hat, was einen bedeutenden Fortschritt bei der Erlangung der behördlichen Genehmigungen darstellt. Das Unternehmen hob jüngste Entwicklungen hervor, einschließlich der vorläufigen Annahme von Lösungen durch die britische CMA für die Genehmigung in Phase 1 und das Auslaufen der Wartefrist nach dem HSR-Gesetz in den USA.
Das Unternehmen arbeitet aktiv mit der FTC an der Überprüfung der vorgeschlagenen Lösungen, während die SAMR in China offiziell ihren Antrag angenommen hat. Die Fusion zielt darauf ab, die wachsende Kundennachfrage nach integrierten EDA- sowie Simulations- und Analyse (S&A)-Softwarelösungen zu erfüllen. Synopsys erwartet, die Transaktion in der ersten Hälfte des Jahres 2025 abzuschließen, und verweist auf starke Kundenunterstützung für die Fusion.
- European Commission approved the Ansys acquisition in Phase 1
- UK CMA provisionally accepted remedies for Phase 1 approval
- U.S. HSR Act waiting period has expired
- China SAMR officially accepted the merger filing
- FTC investigation and review of proposed remedies still pending
- Multiple regulatory approvals still required before deal closure
Insights
The European Commission's Phase 1 approval represents a crucial milestone in Synopsys'
The proposed remedies appear to have effectively addressed competition concerns in multiple jurisdictions, suggesting a well-structured deal that maintains market competition while enabling strategic synergies. The timeline for closing in H1 2025 remains feasible, though the SAMR review could be the determining factor.
This merger approval progress signals a transformative shift in the electronic design automation (EDA) landscape. The integration of Synopsys' EDA capabilities with Ansys' simulation expertise addresses the growing complexity in chip design, particularly important for AI and autonomous systems development. For the semiconductor industry, this means:
- Enhanced ability to simulate and verify complex chip designs before manufacturing
- Reduced time-to-market for new semiconductor products
- Improved optimization of power, performance and area in chip design
The regulatory progress significantly de-risks the transaction, potentially leading to positive market revaluation of Synopsys shares. The deal's strategic rationale becomes more compelling in the context of the AI boom, as integrated EDA and simulation capabilities are important for designing next-generation AI chips. The transaction timing aligns well with the semiconductor industry's super-cycle, potentially allowing Synopsys to capture increased market share during the upturn. The combination could yield annual cost synergies of
"We are very pleased that the EC has approved our pro-competitive transaction in Phase 1. Today's clearance decision follows the strong progress we have made toward gaining regulatory approval across various jurisdictions. Earlier this week, the
Customers continue to express their overwhelming support for the transaction. Together, Synopsys and Ansys can help drive innovation across industries by addressing the rapidly increasing customer need for system design solutions that provide a deeper integration of EDA and Simulation and Analysis (S&A) software. We continue to expect the transaction to close in the first half of 2025."
About Synopsys
Catalyzing the era of pervasive intelligence, Synopsys, Inc. (Nasdaq: SNPS) delivers trusted and comprehensive silicon to systems design solutions, from electronic design automation to silicon IP and system verification and validation. We partner closely with semiconductor and systems customers across a wide range of industries to maximize their R&D capability and productivity, powering innovation today that ignites the ingenuity of tomorrow. Learn more at www.synopsys.com.
INVESTOR CONTACT:
Trey
Synopsys, Inc.
650-584-4289
Synopsys-ir@synopsys.com
EDITORIAL CONTACT:
Cara Walker
Synopsys, Inc.
650-584-5000
corp-pr@synopsys.com
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between Synopsys and Ansys, including, but not limited to, statements regarding the anticipated timing of the closing thereof and the pending regulatory approval of the proposed transaction. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions or the negatives of these words or other comparable terminology to convey uncertainty of future events or outcomes. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.
Many risks, uncertainties and other factors could cause actual future events to differ materially from the forward-looking statements in this communication, including, but not limited to: (i) the completion of the proposed transaction on anticipated terms and timing, anticipated tax treatment and unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, pricing trends, future prospects, credit ratings, business and management strategies which may adversely affect each of Synopsys' and Ansys' business, financial condition, operating results and the price of their common stock, (ii) the failure to satisfy the conditions to the consummation of the proposed transaction, including the adoption of the merger agreement by the stockholders of Ansys and the receipt of certain governmental and regulatory approvals on the terms expected, in a timely manner, or at all, (iii) the risk that such regulatory approvals may result in the imposition of conditions that could adversely affect, following completion of the proposed transaction (if completed), the combined company or the expected benefits of the proposed transaction (including as noted in any forward-looking financial information), (iv) uncertainties as to access to available financing (including any future refinancing of Ansys' or the combined company's debt) to consummate the proposed transaction upon acceptable terms and on a timely basis or at all, (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (vi) the effect of the announcement or pendency of the proposed transaction on Ansys' or Synopsys' business relationships, competition, business, financial condition, and operating results, (vii) risks that the proposed transaction disrupts current plans and operations of Ansys or Synopsys and the ability of Ansys or Synopsys to retain and hire key personnel, (viii) risks related to diverting either management team's attention from ongoing business operations of Ansys or Synopsys, (ix) the outcome of any legal proceedings related to the merger agreement or the proposed transaction, (x) the ability of Synopsys to successfully integrate Ansys' operations and product lines, (xi) the ability of Synopsys to implement its plans, forecasts, expected financial performance and other expectations with respect to Ansys' business or the combined business after the completion of the proposed transaction and realize the benefits expected from the proposed transaction (if completed) as well as manage the scope and size of the combined company, (xii) the ability of Synopsys to manage additional debt and debt covenants as well as successfully de-lever following the proposed transaction and the outcome of any strategic review and any resulting proposed transactions, (xiii) risks associated with third party contracts containing consent and/or other provisions that may be triggered by the proposed transaction, (xiv) uncertainty in the macroeconomic and geopolitical environment and its potential impact on the semiconductor and electronics industries, (xv) uncertainty in the growth of the semiconductor, electronics and artificial intelligence industries, (xvi) the highly competitive industries Synopsys and Ansys operate in, (xvii) actions by the
You should carefully consider the foregoing factors and the other risks and uncertainties that affect the businesses of Synopsys and Ansys described in the "Risk Factors" section of their respective Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed by either of them from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. All forward-looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond Synopsys' and Ansys' control, and are not guarantees of future results. Readers are cautioned not to put undue reliance on forward-looking statements, and Synopsys and Ansys assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. Neither Synopsys nor Ansys gives any assurance that either Synopsys or Ansys will achieve its expectations.
View original content to download multimedia:https://www.prnewswire.com/news-releases/synopsys-responds-to-the-european-commission-approving-its-proposed-acquisition-of-ansys-in-phase-1-302348234.html
SOURCE Synopsys, Inc.
FAQ
When is the Synopsys-Ansys acquisition expected to close?
Which regulatory approvals has SNPS received for the Ansys acquisition?
What is the status of Chinese regulatory approval for SNPS-Ansys deal?
What is the strategic purpose of SNPS acquiring Ansys?
What is the current status of FTC review for SNPS-Ansys merger?
